LB Pharmaceuticals Inc
NGM: LBRXLive Quote
About LB Pharmaceuticals Inc
Healthcare
Biotechnology
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.
📊 Fundamental Analysis
LB Pharmaceuticals Inc demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -15.7%, which indicates that capital utilization is currently under pressure.
At a current price of $24.34, LBRX currently sits at the 77th percentile of its 52-week range (Range: $13.36 - $27.55).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Return on Equity
Weak
Key Financials
Market Cap
$839.37M
Trailing P/E
--
Forward P/E
-5.71
Beta (5Y)
--
52W High
$27.55
52W Low
$13.36
Avg Volume
236K
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App